Raymond K Cross1, Guruprasad Jambaulikar2, Patricia Langenberg3, J Kathleen Tracy3, Joseph F Collins4, Jonathan Katz5, Miguel Regueiro6, David A Schwartz7, Charlene C Quinn3. 1. University of Maryland, Baltimore, Department of Medicine, Division of Gastroenterology and Hepatology, Baltimore, MD, United States. Electronic address: rcross@medicine.umaryland.edu. 2. University of Maryland, Baltimore, Department of Medicine, Division of Gastroenterology and Hepatology, Baltimore, MD, United States. 3. University of Maryland, Baltimore, Department of Epidemiology and Public Health, Baltimore, MD, United States. 4. University of Maryland, Baltimore, Department of Epidemiology and Public Health, Baltimore, MD, United States; Veterans Affairs Cooperative Studies Program, Perry Point, MD, United States. 5. CircleLink Health, Stamford, CT, United States. 6. University of Pittsburgh, Department of Medicine, Division of Gastroenterology, Hepatology, and Nutrition, Pittsburgh, PA, United States. 7. Vanderbilt University, Department of Medicine, Division of Gastroenterology, Hepatology, and Nutrition, Nashville, TN, United States.
Abstract
BACKGROUND:Inflammatory bowel diseases (IBD), comprised of ulcerative colitis and Crohn's disease, are chronic disorders characterized by worsening of symptoms followed by symptom-free periods. Symptoms have a profound negative impact on quality of life and are associated with increased health care utilization. Despite effective treatments, outcomes are suboptimal secondary to nonadherence, medication intolerance, inconsistent monitoring, poor patient knowledge and limited access to care. OBJECTIVES: Compare disease activity and quality of life over 1 year in a randomized trial of IBD patients receivingstandard care versus telemedicine. METHODS:Patients evaluated at 3 IBD referral centers with worsening symptoms within the last 2 years are eligible for randomization to one of two interventions or standard care. The interventions consist of either every other week or weekly assessment of symptoms, side effects, weight and delivery of medication prompts and education via texts to the participant's mobile phone. Individualized alerts and action plans are created on a secure portal. Participants in the standard care group undergo routine and urgent follow-up visits and telephone calls. The primary outcomes group comparisons of changes in disease activity and quality of life scores from baseline to 6 and 12 months. CONCLUSIONS: Methods such as telemedicine are needed to improve monitoring, adherence, self-efficacy, and patient knowledge in IBD. If effective, telemedicine should decrease symptoms, improve quality of life, and decrease health care utilization. The burden associated with use of telemedicine for patients and providers needs to be assessed. The trial is ongoing and will be completed in July 2016.
RCT Entities:
BACKGROUND:Inflammatory bowel diseases (IBD), comprised of ulcerative colitis and Crohn's disease, are chronic disorders characterized by worsening of symptoms followed by symptom-free periods. Symptoms have a profound negative impact on quality of life and are associated with increased health care utilization. Despite effective treatments, outcomes are suboptimal secondary to nonadherence, medication intolerance, inconsistent monitoring, poor patient knowledge and limited access to care. OBJECTIVES: Compare disease activity and quality of life over 1 year in a randomized trial of IBD patients receiving standard care versus telemedicine. METHODS:Patients evaluated at 3 IBD referral centers with worsening symptoms within the last 2 years are eligible for randomization to one of two interventions or standard care. The interventions consist of either every other week or weekly assessment of symptoms, side effects, weight and delivery of medication prompts and education via texts to the participant's mobile phone. Individualized alerts and action plans are created on a secure portal. Participants in the standard care group undergo routine and urgent follow-up visits and telephone calls. The primary outcomes group comparisons of changes in disease activity and quality of life scores from baseline to 6 and 12 months. CONCLUSIONS: Methods such as telemedicine are needed to improve monitoring, adherence, self-efficacy, and patient knowledge in IBD. If effective, telemedicine should decrease symptoms, improve quality of life, and decrease health care utilization. The burden associated with use of telemedicine for patients and providers needs to be assessed. The trial is ongoing and will be completed in July 2016.
Authors: Ameer Abutaleb; Andrea Buchwald; Kenechukwu Chudy-Onwugaje; Patricia Langenberg; Miguel Regueiro; David A Schwartz; J Kathleen Tracy; Leyla Ghazi; Seema A Patil; Sandra M Quezada; Katharine M Russman; Charlene C Quinn; Guruprasad Jambaulikar; Dawn B Beaulieu; Sara Horst; Raymond K Cross Journal: Inflamm Bowel Dis Date: 2018-09-15 Impact factor: 5.325
Authors: Girish Hiremath; Adrian Chapa-Rodriguez; David A Katzka; Jonathan M Spergel; Benjamin Gold; Albert J Bredenoord; Evan S Dellon; Jeannie Huang; Sandeep K Gupta Journal: Transl Sci Rare Dis Date: 2022-04-13
Authors: Zaid Bilgrami; Ameer Abutaleb; Kenechukwu Chudy-Onwugaje; Patricia Langenberg; Miguel Regueiro; David A Schwartz; J Kathleen Tracy; Leyla Ghazi; Seema A Patil; Sandra M Quezada; Katharine M Russman; Charlene C Quinn; Guruprasad Jambaulikar; Dawn B Beaulieu; Sara Horst; Raymond K Cross Journal: Dig Dis Sci Date: 2019-01-02 Impact factor: 3.199
Authors: Eun Soo Kim; Yoo Jin Lee; Byung Ik Jang; Kyeong Ok Kim; Eun Young Kim; Hyun Seok Lee; Seong Woo Jeon; Sang Gyu Kwak Journal: Korean J Intern Med Date: 2018-01-17 Impact factor: 2.884